LOGIN  |  REGISTER
Terns Pharmaceuticals

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 134.36
0.25 0.19
1.83M
1.73B
US$ 232.440B
US$ 543.89
3.29 0.61
470,785
356.18M
US$ 193.720B
US$ 429.30
1.54 0.36
904,333
382.50M
US$ 164.210B
US$ 104.01
0.38 0.37
1.92M
1.47B
US$ 152.890B
US$ 395.27
3.46 0.88
328,637
381.22M
US$ 150.680B
US$ 203.49
0.99 0.49
923,928
722.28M
US$ 146.980B
US$ 88.39
0.11 0.12
2.07M
1.28B
US$ 113.140B
US$ 718.01
12.56 1.78
241,566
126.94M
US$ 91.140B
US$ 176.54
-0.73 -0.41
748,353
290.01M
US$ 51.200B
US$ 76.54
-0.48 -0.62
971,709
589.80M
US$ 45.140B
US$ 547.01
4.30 0.79
594,023
81.88M
US$ 44.790B
US$ 87.78
-1.52 -1.70
1.37M
494.60M
US$ 43.420B
US$ 164.77
2.79 1.72
622,564
242.01M
US$ 39.880B
US$ 254.00
-1.88 -0.73
247,779
146.80M
US$ 37.290B
US$ 121.00
0.34 0.28
571,737
285.60M
US$ 34.560B
US$ 82.93
-0.65 -0.78
3.32M
390.60M
US$ 32.390B
US$ 165.27
0.62 0.38
403,570
181.50M
US$ 30.000B
US$ 1.00
3.43 0.28
24,512
21.10M
US$ 25.510B
US$ 240.63
2.38 1.00
124,259
98.71M
US$ 23.750B
US$ 259.12
-0.88 -0.34
144,909
83.64M
US$ 21.670B
US$ 162.00
0.43 0.27
852,479
132.02M
US$ 21.390B
US$ 301.05
-0.49 -0.16
977,141
70.14M
US$ 21.120B
US$ 350.22
-1.70 -0.48
150,830
59.38M
US$ 20.800B
US$ 179.00
2.40 1.36
290,956
111.62M
US$ 19.980B
US$ 94.51
1.01 1.08
523,486
199.07M
US$ 18.810B
US$ 222.93
1.71 0.77
188,486
72.42M
US$ 16.140B
US$ 101.00
0.66 0.66
1.42M
158.60M
US$ 16.020B
US$ 30.66
-0.47 -1.51
953,503
510.59M
US$ 15.650B
US$ 73.30
0.28 0.38
2.78M
199.58M
US$ 14.630B
US$ 64.78
-0.52 -0.80
1.17M
225.72M
US$ 14.620B
US$ 30.28
0.12 0.40
202,648
435.99M
US$ 13.200B
US$ 150.10
-0.72 -0.48
938,226
82.56M
US$ 12.390B
US$ 101.31
0.41 0.41
503,157
121.70M
US$ 12.330B
US$ 47.54
-1.10 -2.26
553,572
222.26M
US$ 10.570B
US$ 321.50
-4.53 -1.39
142,068
31.08M
US$ 9.990B
US$ 53.36
-0.50 -0.93
1.61M
185.08M
US$ 9.880B
US$ 251.43
1.69 0.68
110,839
38.38M
US$ 9.650B
US$ 60.81
1.63 2.75
6.18M
152.40M
US$ 9.270B
US$ 167.57
-3.77 -2.20
866,151
53.54M
US$ 8.970B
US$ 157.12
-0.37 -0.23
152,385
51.14M
US$ 8.040B
US$ 127.47
0.51 0.40
380,659
56.03M
US$ 7.140B
US$ 58.81
-1.76 -2.91
1.35M
113.74M
US$ 6.690B
US$ 42.13
-0.33 -0.78
957,076
151.60M
US$ 6.390B
US$ 49.76
-0.42 -0.84
811,118
123.56M
US$ 6.150B
US$ 251.56
0.91 0.36
71,212
22.92M
US$ 5.770B
US$ 103.80
0.14 0.14
139,126
55.14M
US$ 5.720B
US$ 122.65
1.11 0.91
130,527
46.44M
US$ 5.700B
US$ 80.41
0.79 0.99
268,658
69.53M
US$ 5.590B
US$ 93.60
0.09 0.10
267,806
58.28M
US$ 5.460B
US$ 13.72
-0.04 -0.29
465,252
352.16M
US$ 4.830B
US$ 79.97
0.00 0.00
0
58.56M
US$ 4.680B
US$ 142.47
-0.31 -0.22
173,069
31.30M
US$ 4.460B
US$ 128.32
0.63 0.49
717,707
33.56M
US$ 4.310B
US$ 56.05
0.40 0.72
205,581
74.03M
US$ 4.150B
US$ 121.00
-0.19 -0.16
131,208
33.54M
US$ 4.060B
US$ 79.98
-0.20 -0.25
155,793
49.41M
US$ 3.950B
US$ 129.04
-1.68 -1.29
201,367
29.97M
US$ 3.870B
US$ 76.00
-0.24 -0.31
146,468
50.22M
US$ 3.820B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 11.75
0.10 0.86
658,888
283.24M
US$ 3.330B
US$ 135.44
-0.74 -0.54
289,442
24.48M
US$ 3.320B
US$ 58.00
-0.18 -0.31
194,203
54.11M
US$ 3.140B
US$ 46.13
0.05 0.11
424,877
54.30M
US$ 2.500B
US$ 22.23
0.27 1.23
368,509
101.66M
US$ 2.260B
US$ 37.47
-0.21 -0.56
379,093
59.58M
US$ 2.230B
US$ 30.19
0.00 0.00
1.88M
67.26M
US$ 2.030B
US$ 84.39
0.54 0.64
135,692
22.48M
US$ 1.900B
US$ 17.60
-0.28 -1.57
954,326
108.20M
US$ 1.900B
US$ 54.33
0.11 0.20
180,185
30.89M
US$ 1.680B
US$ 46.77
-0.79 -1.66
2.04M
33.60M
US$ 1.570B
US$ 10.98
0.02 0.18
1.47M
141.77M
US$ 1.560B
US$ 31.76
0.37 1.18
165,548
48.75M
US$ 1.550B
US$ 33.23
0.38 1.16
1.02M
45.69M
US$ 1.520B
US$ 30.72
-0.13 -0.42
69,538
41.92M
US$ 1.290B
US$ 43.30
-1.06 -2.39
181,990
28.76M
US$ 1.250B
US$ 24.61
0.13 0.53
91,568
49.60M
US$ 1.220B
US$ 8.96
-0.41 -4.38
1.44M
134.56M
US$ 1.200B
US$ 15.16
-0.05 -0.33
595,685
76.25M
US$ 1.160B
US$ 5.34
0.11 2.10
7.70M
216.94M
US$ 1.160B
US$ 20.90
0.32 1.55
107,612
52.94M
US$ 1.110B
US$ 16.79
-0.29 -1.70
991,342
65.68M
US$ 1.100B
US$ 13.09
0.00 0.00
0
83.72M
US$ 1.100B
US$ 22.84
0.09 0.40
471,803
46.39M
US$ 1.060B
US$ 13.49
-0.03 -0.22
1.40M
77.16M
US$ 1.040B
US$ 19.08
-0.41 -2.10
576,406
53.63M
US$ 1.020B
US$ 7.55
0.15 2.03
2.12M
128.36M
US$ 969.120M
US$ 6.34
0.11 1.77
559,352
146.95M
US$ 931.660M
US$ 15.14
-0.18 -1.17
86,396
61.52M
US$ 931.410M
US$ 1.36
0.02 1.49
1.03M
672.80M
US$ 915.010M
US$ 17.86
0.30 1.71
470,489
49.28M
US$ 880.140M
US$ 61.79
0.25 0.41
135,682
12.67M
US$ 782.880M
US$ 18.47
0.04 0.22
454,797
41.94M
US$ 774.630M
US$ 9.00
-0.29 -3.12
407,742
77.11M
US$ 693.990M
US$ 18.93
0.30 1.61
177,902
35.82M
US$ 678.070M
US$ 19.77
-0.34 -1.69
160,871
30.59M
US$ 604.760M
US$ 20.30
0.29 1.45
303,376
28.01M
US$ 568.600M
US$ 12.35
-0.03 -0.24
74,473
45.96M
US$ 567.610M
US$ 22.48
0.34 1.54
78,686
24.22M
US$ 544.470M
US$ 13.05
-0.09 -0.68
1.80M
40.30M
US$ 525.920M
US$ 1.36
-0.01 -0.80
727,924
372.26M
US$ 505.900M
US$ 5.45
-0.18 -3.20
380,607
91.04M
US$ 496.170M
US$ 3.76
0.15 4.16
1.44M
128.81M
US$ 484.330M
US$ 3.45
0.05 1.47
100,157
139.82M
US$ 482.380M
US$ 10.93
-0.15 -1.35
305,479
44.01M
US$ 481.030M
US$ 1.61
0.12 8.05
13.67M
294.32M
US$ 473.860M
US$ 7.19
0.34 4.96
171,929
65.37M
US$ 470.010M
US$ 12.70
0.19 1.52
662,151
36.20M
US$ 459.740M
US$ 29.99
0.99 3.41
274,034
14.29M
US$ 428.560M
US$ 11.12
0.06 0.54
294,938
38.21M
US$ 424.900M
US$ 17.24
0.70 4.23
86,379
23.48M
US$ 404.800M
US$ 6.48
0.38 6.24
148,512
62.30M
US$ 403.390M
US$ 9.58
0.19 2.02
408,891
40.47M
US$ 387.700M
US$ 2.01
0.05 2.55
4.08M
186.64M
US$ 375.150M
US$ 40.40
0.86 2.18
294,844
9.27M
US$ 374.510M
US$ 8.80
0.08 0.92
274,057
41.23M
US$ 362.820M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 6.80
-0.12 -1.73
747,577
49.57M
US$ 337.080M
US$ 5.27
-0.06 -1.13
437,166
58.52M
US$ 308.400M
US$ 0.50
0.01 2.45
2.57M
595.33M
US$ 298.860M
US$ 3.23
-0.15 -4.44
1.36M
92.44M
US$ 298.580M
US$ 10.00
-0.42 -4.03
154,549
29.85M
US$ 298.500M
US$ 7.83
0.13 1.69
28,379
37.43M
US$ 293.080M
US$ 2.11
0.13 6.57
12.68M
138.40M
US$ 292.020M
US$ 7.15
0.06 0.85
182,016
38.94M
US$ 278.420M
US$ 10.06
0.05 0.50
62,749
27.60M
US$ 277.660M
US$ 4.75
-0.19 -3.85
55,744
55.19M
US$ 262.150M
US$ 29.33
-0.61 -2.04
79,959
8.74M
US$ 256.340M
US$ 3.68
0.29 8.55
967,702
67.59M
US$ 248.730M
US$ 10.12
-0.01 -0.10
193,142
24.00M
US$ 242.880M
US$ 12.81
0.01 0.08
66,134
18.82M
US$ 241.080M
US$ 28.00
0.00 0.00
0
8.53M
US$ 238.840M
US$ 2.24
-0.005 -0.22
283,443
105.48M
US$ 235.750M
US$ 6.65
0.04 0.61
469,065
34.82M
US$ 231.550M
US$ 3.08
0.02 0.65
578,548
74.59M
US$ 229.740M
C$ 0.81
0.00 0.00
23,215
282.82M
C$ 229.080M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 4.21
0.05 1.20
204,053
50.40M
US$ 212.180M
US$ 58.44
0.95 1.65
18,769
3.39M
US$ 198.110M
US$ 2.20
0.04 1.85
81,211
84.73M
US$ 186.410M
US$ 3.34
-0.08 -2.34
858,478
55.65M
US$ 185.870M
US$ 5.99
-0.10 -1.64
9,653
30.03M
US$ 179.880M
US$ 7.49
0.07 0.94
168,096
23.82M
US$ 178.410M
US$ 20.78
0.46 2.26
123,469
8.46M
US$ 175.800M
US$ 3.62
-0.02 -0.55
199,327
45.84M
US$ 165.940M
US$ 6.70
0.24 3.72
59,417
24.26M
US$ 162.540M
US$ 47.82
2.77 6.15
54,387
3.26M
US$ 155.890M
US$ 5.07
0.17 3.47
58,506
30.49M
US$ 154.580M
US$ 13.16
0.07 0.53
178,969
11.61M
US$ 152.790M
US$ 1.45
0.06 4.24
936,090
100.56M
US$ 145.710M
US$ 5.42
0.25 4.84
195,737
26.22M
US$ 142.110M
US$ 3.68
0.14 3.95
77,692
37.72M
US$ 138.810M
US$ 8.63
0.30 3.60
51,795
16.04M
US$ 138.430M
US$ 3.80
0.09 2.43
161,765
35.94M
US$ 136.570M
US$ 6.16
-0.01 -0.16
39,117
21.26M
US$ 130.960M
US$ 7.05
0.08 1.15
453,302
17.64M
US$ 124.360M
US$ 2.78
0.06 2.21
291,534
39.49M
US$ 109.780M
US$ 2.18
-0.03 -1.36
67,855
49.50M
US$ 107.910M
US$ 0.66
0.02 2.42
322,496
156.55M
US$ 102.700M
US$ 2.91
0.00 0.00
33,697
34.31M
US$ 99.840M
US$ 15.60
0.19 1.23
16,544
6.27M
US$ 97.810M
US$ 0.68
-0.0091 -1.31
47,702
139.01M
US$ 95.080M
US$ 8.00
-0.21 -2.56
58,657
10.64M
US$ 85.120M
US$ 2.58
0.13 5.31
68,775
32.80M
US$ 84.620M
US$ 2.20
0.05 2.33
152,432
37.64M
US$ 82.810M
US$ 2.04
0.13 6.81
41,200
39.39M
US$ 80.360M
US$ 4.74
-0.02 -0.42
96,223
16.39M
US$ 77.690M
US$ 1.78
0.00 0.00
103,034
43.09M
US$ 76.700M
US$ 1.27
0.00 0.00
144,833
59.23M
US$ 75.220M
US$ 2.35
-0.34 -12.64
236,267
31.85M
US$ 74.850M
US$ 2.62
0.12 4.80
2.05M
28.03M
US$ 73.440M
US$ 4.10
0.15 3.80
49,786
17.54M
US$ 71.910M
US$ 3.26
-0.23 -6.53
68,164
22.00M
US$ 71.760M
US$ 2.10
0.01 0.48
308,827
33.70M
US$ 70.740M
US$ 1.36
0.01 0.74
734,244
49.57M
US$ 67.420M
US$ 0.70
-0.05 -6.85
978,670
95.97M
US$ 67.180M
US$ 1.09
0.09 8.90
397,752
60.93M
US$ 66.350M
US$ 1.11
0.06 5.71
2.21M
59.34M
US$ 65.870M
US$ 2.05
0.02 0.99
262,795
32.02M
US$ 65.580M
C$ 0.56
0.01 1.82
134,000
113.40M
C$ 63.500M
US$ 2.17
0.09 4.33
12,200
29.25M
US$ 63.470M
US$ 2.09
-0.07 -3.24
7,302
30.25M
US$ 63.220M
US$ 3.50
0.00 0.00
0
18.00M
US$ 63.000M
US$ 3.28
0.05 1.55
91,090
18.34M
US$ 60.160M
US$ 2.27
0.04 1.79
46,934
26.08M
US$ 59.200M
US$ 1.59
0.02 1.27
75,427
37.10M
US$ 58.990M
US$ 1.04
0.03 2.97
1.15M
56.57M
US$ 58.830M
US$ 2.72
0.19 7.51
690,449
20.75M
US$ 56.440M
US$ 20.01
0.00 0.00
0
2.54M
US$ 50.830M
US$ 0.65
0.02 3.98
518,547
77.89M
US$ 50.710M
C$ 0.40
0.00 0.00
23,500
119.77M
C$ 47.910M
US$ 0.11
0.003 2.73
187,491
417.59M
US$ 47.190M
US$ 0.81
0.08 11.71
814,201
57.89M
US$ 46.890M
C$ 0.19
-0.01 -5.13
191,549
247.78M
C$ 45.840M
US$ 4.03
0.05 1.26
55,549
10.54M
US$ 42.480M
US$ 0.28
0.002 0.73
765,347
145.47M
US$ 40.300M
US$ 7.62
0.26 3.53
5,234
5.25M
US$ 40.010M
US$ 3.92
-0.81 -17.12
66
10.07M
US$ 39.470M
US$ 5.84
0.48 8.96
366,820
6.55M
US$ 38.250M
US$ 1.30
0.01 0.78
67,588
26.67M
US$ 34.670M
US$ 9.25
-0.51 -5.23
119,443
3.73M
US$ 34.500M
US$ 3.99
0.16 4.18
28,528
8.27M
US$ 33.000M
US$ 1.57
0.07 4.67
8,835
20.24M
US$ 31.780M
US$ 2.04
0.00 0.00
0
15.37M
US$ 31.350M
C$ 0.34
0.04 13.33
21,400
90.89M
C$ 30.900M
US$ 0.76
0.06 8.57
552,571
40.14M
US$ 30.510M
C$ 0.25
0.00 0.00
247,584
113.10M
C$ 28.280M
US$ 3.31
0.08 2.48
10,708
8.53M
US$ 28.230M
US$ 0.69
-0.02 -3.39
64,473
38.39M
US$ 26.340M
US$ 1.17
0.09 8.33
2.20M
22.45M
US$ 26.270M
US$ 4.23
0.40 10.44
957,850
5.89M
US$ 24.910M
C$ 0.32
0.00 0.00
0
77.42M
C$ 24.770M
C$ 0.26
0.005 1.96
95,900
93.38M
C$ 24.280M
C$ 0.09
-0.005 -5.56
26,263
270.17M
C$ 22.960M
US$ 0.73
0.04 5.80
67,077
30.84M
US$ 22.510M
US$ 0.96
0.01 1.07
28,159
22.90M
US$ 21.980M
C$ 0.14
0.005 3.85
3,373
159.67M
C$ 21.560M
US$ 0.67
0.03 4.11
73,923
29.94M
US$ 20.030M
US$ 0.45
-0.02 -5.01
667,278
43.62M
US$ 19.450M
US$ 0.71
0.02 3.66
240,757
27.52M
US$ 19.430M
US$ 2.67
-0.28 -9.56
291,375
7.26M
US$ 19.370M
US$ 12.88
1.58 13.98
35,701
1.48M
US$ 19.060M
US$ 2.65
0.03 1.15
9,508
6.79M
US$ 17.990M
US$ 1.24
0.00 0.00
128,503
13.96M
US$ 17.310M
US$ 0.31
0.00 0.00
0
52.24M
US$ 16.390M
C$ 0.05
0.00 0.00
0
320.55M
C$ 16.030M
US$ 0.77
0.00 0.00
0
20.63M
US$ 15.890M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
C$ 0.26
0.00 0.00
0
59.60M
C$ 15.500M
US$ 0.92
0.0098 1.08
12,336
16.64M
US$ 15.310M
US$ 2.04
0.00 0.00
0
7.09M
US$ 14.440M
US$ 1.05
0.07 7.14
73,983
13.30M
US$ 13.960M
US$ 0.42
-0.01 -2.33
222,494
31.90M
US$ 13.400M
US$ 0.18
0.0002 0.11
1.04M
72.19M
US$ 12.850M
C$ 0.13
0.00 0.00
0
100.02M
C$ 12.500M
C$ 0.06
0.00 0.00
0
217.73M
C$ 11.980M
US$ 5.66
-0.04 -0.70
135,314
2.05M
US$ 11.600M
US$ 0.61
0.00 0.00
0
19.01M
US$ 11.530M
US$ 0.71
0.01 1.43
25,027
14.59M
US$ 10.360M
US$ 2.33
-0.25 -9.69
60,629
4.17M
US$ 9.720M
US$ 4.58
0.00 0.00
0
2.04M
US$ 9.340M
US$ 0.38
-0.009 -2.31
10,670
24.39M
US$ 9.290M
US$ 0.29
0.004 1.40
400,261
31.93M
US$ 9.260M
US$ 1.84
0.01 0.55
203,906
4.81M
US$ 8.850M
US$ 3.54
-0.08 -2.21
124,948
2.46M
US$ 8.710M
US$ 1.27
0.00 0.00
0
6.24M
US$ 7.920M
US$ 0.67
-0.0027 -0.40
1.03M
10.63M
US$ 7.120M
US$ 2.57
0.00 0.00
19,663
2.71M
US$ 6.960M
US$ 0.60
0.006 1.02
21,444
11.07M
US$ 6.610M
US$ 0.86
0.03 3.08
80,648
6.67M
US$ 5.740M
C$ 0.11
0.00 0.00
0
48.23M
C$ 5.060M
C$ 0.05
0.00 0.00
0
101.29M
C$ 5.060M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
C$ 0.01
0.00 0.00
2.96M
451.63M
C$ 4.520M
US$ 0.06
0.00 0.00
0
73.90M
US$ 4.510M
US$ 0.67
-2.44 -78.46
58,887
6.63M
US$ 4.440M
US$ 0.28
-0.009 -3.10
912,646
15.58M
US$ 4.380M
US$ 0.74
-0.01 -1.62
15,270
5.85M
US$ 4.330M
US$ 0.34
0.00 0.00
0
11.88M
US$ 4.040M
US$ 0.78
0.00 0.00
0
4.85M
US$ 3.780M
US$ 0.94
-0.02 -1.99
237,248
3.75M
US$ 3.510M
US$ 3.55
-0.23 -6.08
45,442
980,321
US$ 3.480M
US$ 0.04
-0.004 -10.26
110,000
96.71M
US$ 3.380M
US$ 0.54
-0.02 -3.25
2.72M
6.00M
US$ 3.250M
US$ 1.44
0.01 0.70
94,591
2.22M
US$ 3.200M
US$ 0.97
-0.0034 -0.35
116,504
3.14M
US$ 3.050M
US$ 0.14
0.01 7.69
29,907
21.04M
US$ 2.950M
US$ 1.45
0.00 0.00
0
1.82M
US$ 2.640M
US$ 0.50
0.00 0.00
0
5.24M
US$ 2.610M
US$ 1.45
-0.07 -4.61
123,794
1.77M
US$ 2.570M
US$ 0.21
0.00 0.00
0
10.59M
US$ 2.220M
US$ 3.57
-0.03 -0.83
9,578
536,908
US$ 1.920M
US$ 0.23
-0.01 -4.51
1.53M
8.00M
US$ 1.860M
US$ 2.37
-0.05 -2.07
66,590
729,980
US$ 1.730M
US$ 0.47
0.00 0.00
0
3.20M
US$ 1.520M
US$ 0.08
0.00 0.00
0
16.67M
US$ 1.370M
US$ 0.99
-0.01 -1.00
113,024
962,637
US$ 953K
US$ 1.63
0.01 0.62
15,751
552,854
US$ 901K
US$ 0.20
-0.02 -9.79
2.13M
4.37M
US$ 865K
US$ 0.03
0.00 0.00
0
25.04M
US$ 851K
US$ 0.07
0.00 0.00
0
7.26M
US$ 508K
US$ 1.15
0.00 0.00
0
418,049
US$ 481K
C$ 0.005
0.00 0.00
0
59.81M
C$ 299K
US$ 0.06
0.00 0.00
0
1.78M
US$ 100K
US$ 0.00
0.00 0.00
0
29.91M
US$ -
US$ 0.00
0.00 0.00
0
40.35M
US$ -
US$ 0.00
0.00 0.00
0
15.85M
US$ -
US$ 0.00
0.00 0.00
0
6.39M
US$ -
US$ 0.00
-0.0001 -100.00
44.21M
855.04M
US$ -
C$ 0.40
0.00 0.00
0
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Stocks


CapsoVision Announces Closing of Initial Public Offering

SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2,... Read more


IceCure Medical Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

CAESAREA, Israel, July 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced preliminary financial results as of and for the three and six months ended June 30, 2025. The Company expects product sales of approximately $525,000 for the three months ended June 30,... Read more


MDxHealth Appoints Michael Holder to Board of Directors and Announces Management Change

IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board,... Read more


Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry

PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the AERA Eustachian Tube Balloon Dilation System in children. This inaugural enrollment marks the focused effort to measure the ongoing, real-world... Read more


Intuitive’s da Vinci 5 Surgical System Receives CE Mark

Fifth-generation da Vinci surgical system approved for use in Europe across multiple procedures SUNNYVALE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the da Vinci 5 Surgical System has received CE mark approval for adult and pediatric use in Europe for minimally invasive endoscopic procedures across abdominopelvic... Read more


Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase

RA'ANANA, Israel, July 02, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has secured a binding $22.5 million purchase order for its FDA-cleared ART100 system, representing a major commercial inflection point for the Company. The order was placed by a privately held company headquartered outside... Read more


Biomerica: InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code

PLA Code issuance by the American Medical Association CPT editorial panel marks a meaningful step toward attaining health insurance reimbursement and expanded patient access for inFoods® IBS inFoods® IBS provides personalized identification of food triggers to substantially improve IBS-related symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company... Read more


Medical City Dallas Hospital Adopts Perimeter Medical Imaging AI's Innovative OCT Imaging Technology for Surgery

Deployment follows participation in pivotal trial of Perimeter's next-gen technology with AI for breast-conserving surgeries TORONTO and DALLAS, July 2, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced today that Medical City Dallas Hospital, an award-winning 899-bed acute care hospital in the Dallas-Fort Worth area, has adopted the company's current... Read more


CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada.  DrugSorb-ATR is an FDA-designated Breakthrough Device designed to reduce the severity of bleeding... Read more


FONAR Board of Directors Appoints Independent Director

Melville, New York--(Newsfile Corp. - July 2, 2025) - FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning, today announced that on July 2, 2025, its board of directors appointed Mr. Robert M. Carrino as an independent director of the Company's board of directors. This appointment fills a vacancy on the board left by Ms. Claudette J.V. Chan, who recently retired from her position. The Company is very grateful for Ms. Chan's years of service and loyalty to FONA... Read more


Nuwellis Appoints John Erb as Chief Executive Officer

WHO WHAT WHERE WHEN HOW John Erb Appointed as Chief Executive Officer (no longer serving in an interim capacity) Nuwellis Headquarters Effective June 27, 2025 Appointment confirmed by the Board of Directors following his interim leadership MINNEAPOLIS, July 02, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to advancing solutions in fluid management, today announced the appointment of John Erb as... Read more


Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

AUSTIN, Texas / Jul 01, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data on its tissue-free MRD assay. Signatera... Read more


First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled “First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,” the publication is the first peer-reviewed literature... Read more


Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation... Read more


ReShape Lifesciences Granted U.S. Patent Related to an Intragastric Balloon System

Patent Enhances and Broadens the Company’s Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on July 8, 2025 the U.S. Patent and Trademark Office (USPTO) will issue U.S. Patent 12,350,179, entitled, “Intragastric Device.” The patent, related... Read more


Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance

Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos’ Patented and FDA-Cleared Oral Appliance Treatment LITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced that its VidaSleep™ oral appliance, featuring Vivos’... Read more


Envoy Medical Expands Global Patent Portfolio with New Issuances in Australia

White Bear Lake, Minnesota--(Newsfile Corp. - July 1, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents, further strengthening its intellectual property portfolio in Australia. The Australian Patent Office has issued the following three patents to Envoy Medical Corporation: Australian Patent No. 2021391396 on April... Read more


Nano-X Imaging Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC

Nanox.ARC delivers advanced 3D imaging with proprietary cold cathode technology Clinical studies show superior diagnostic performance to X-ray with reduced radiation exposure compared to CT PETACH TIKVA, Israel, July 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced a clinical and educational collaboration with Keiser University, Florida’s largest private, non-profit... Read more


New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices

The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs)  GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a new study describing the bioinductive effects of its antibiotic-eluting CIED... Read more


Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated a statistically significant and clinically meaningful benefit across multiple measures of pain and in a post-hoc analysis significantly delayed the need for opioid pain medication for patients with unresectable, locally advanced pancreatic adenocarcinoma A significant delay in deterioration across measures of health status was observed, preserving quality of life longer in patients treated with... Read more


Zynex Announces Steven Dyson as New CEO

ENGLEWOOD, Colo., June 30, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Steven Dyson as Chief Executive Officer. His employment will begin on August 18, 2025. Thomas Sandgaard, Founder of Zynex and Chairman of the Board since the company's inception in 1996, will remain actively... Read more


INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute

MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, is excited to announce the addition of Platelet-Rich Plasma (PRP) therapy to its comprehensive suite of fertility services at its Wisconsin Fertility Institute center. This cutting-edge treatment offers additional options for individuals and couples facing fertility challenges,... Read more


Autonomix Medical Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study

Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative... Read more


Spectral AI Announces Submission to FDA of its DeepView® System

DALLAS, June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and artificial intelligence (“AI”) algorithms to predict burn healing potential, today announced the submission of its De Novo 510k marketing clearance application to the... Read more


NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

FORT MYERS, Fla. / Jun 30, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex treatment decisions more confiden... Read more


Bone Biologics Announces Closing of $5.0 Million Public Offering

BURLINGTON, Mass. / Jun 30, 2025 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term... Read more


Vicarious Surgical Announces Election of New Directors

WALTHAM, Mass. / Jun 30, 2025 / Business Wire / Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company’s 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Vicarious... Read more


RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening

Cost-Efficient Methodology Aims To Reduce Reliance On Expensive Diagnostic Procedures Such As MRI, CT Scans, PET Scans, and Echocardiograms APOLLO BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of... Read more


Autonomix Medical Granted New U.S. Patent for Innovative Catheter-Based Platform Technology

Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing... Read more


Bone Biologics Files Patent Application for Bone Regeneration Technology

BURLINGTON, Mass. / Jun 27, 2025 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein. The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions. “This patent... Read more


bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

SAN ANTONIO / Jun 26, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on cancer diagnostics and targeted therapeutics, will present findings today related to the discovery of a potential broad-spectrum cancer therapy that is the subject of the Company’s recently issued U.S. Patent No. 12,305,171 and the notification of patent grant from the China National Intellectual Property Administration. The presentation... Read more


Ocumetics Technology Completes Virtual Site Initiation for First-In-Human Clinical Study of Accommodating Intraocular Lens

Calgary, Alberta – TheNewswire - June 26, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the successful completion of a virtual site initiation visit at its clinical partner site in Mexico City. This critical milestone confirms that the investigative site is fully prepared to conduct the upcoming first-in-human (FIH) clinical study of its... Read more


DarioHealth and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide

Dario and GreenKey Join Forces to Target $150 Billion Sleep Apnea Market, Addressing 29 Million Americans with Unmet Needs Through Integrated Chronic Care Solution NEW YORK and SAN FRANCISCO, June 26, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ('Dario' or the 'Company'), a leader in the global digital health market, today announced a strategic commercial agreement with GreenKey Health ('GreenKey'), an innovator in value-based sleep health solutions, to bring... Read more


New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

Important Study Shows Vivos Technology to be a Safe and Highly Effective, Non-Surgical Alternative to Surgical Removal of Tonsils and Adenoids in Children LITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking... Read more


NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation

ENvue Targeting $10 Billion+ Market Opportunity with Scalable AI-Enhanced Clinical Robotics TYLER, Texas / Jun 26, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the official launch of a next-generation robotic development initiative within its ENvue Medical (“ENvue” or “ENvue Medical”) division. The new platform,... Read more


Sensus Healthcare Engages Radiology Oncology Systems (ROS) as Primary Distribution Partner for its SRT Systems to Radiation Oncologists

Strategic Partnership Targets U.S. Market Expansion of Superficial Radiotherapy Systems into Hospital-Based and Freestanding Oncology Centers BOCA RATON, Fla. / Jun 26, 2025 / Business Wire / Sensus Healthcare, Inc. (Nasdaq: SRTS) (Sensus or the Company), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it has entered into a strategic... Read more


Lifeward Announces Closing of $2.6 Million Public Offering

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the closing of its previously announced public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s... Read more


Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported... Read more


Tempus AI: Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing

Peer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool validated with real-world patient data ALISO VIEJO, Calif. / Jun 25, 2025 / Business Wire / Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of the Ambry CARE Program® (CARE)... Read more


Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Regulatory Clearances Support Glaukos’ Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks the Company’s First Regulatory Clearances Under the New EU Regulatory Framework ALISO VIEJO, Calif. / Jun 25, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced... Read more


Zynex Announces Award of UK Patent for Non-Invasive Detection of Sepsis

ENGLEWOOD, Colo., June 25, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been awarded UK patent 2617515 for a multiparameter, noninvasive sepsis monitor. Sepsis is a life-threatening condition characterized by systemic inflammation and organ dysfunction caused by... Read more


Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene... Read more


INVO Fertility Receives Notice of Allowance for Modified INVOcell Device Patent

SARASOTA, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility sector, today announced it has received a notice of allowance on a new patent for a modified version of the Company’s proprietary INVOcell device. The new patent extends intellectual property protection on the Company’s INVOcell device through 2040 based on a modified design which reflects feedback... Read more


Tivic Health Systems Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Breakthrough Findings to be Reported Later this Year and Applied to Upcoming Phase I Clinical Trial FREMONT, Calif. / Jun 25, 2025 / Business Wire / Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study visits in the Optimization Study for its patent pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Initial... Read more


ReShape Lifesciences Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a key international patent from the Australian Patent Office for its Diabetes Neuromodulation technology. Patent number 2019252920, entitled, “Simultaneous Multi-Site... Read more


Stryker receives FDA clearance for Incompass Total Ankle System

Streamlining total ankle replacement with data-driven implants and surgical flexibility PORTAGE, Mich. / Jun 25, 2025 / Business Wire / Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates... Read more


OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA. Oral OPK-88006 is being developed pursuant to a collaboration... Read more


InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States. The PMA approval is backed by best-in-class evidence from the Company’s C-GUARDIANS pivotal trial, first presented at the... Read more


bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

Company research targets topical application for treatment of skin cancers SAN ANTONIO, Texas / Jun 24, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company’s novel composition and method for selectively killing... Read more


Ocumetics Technology: First-In-Human Study of Accommodating Intraocular Lens Set to Begin June 26, 2025

Calgary, Alberta – TheNewswire - June 24, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to confirm the culmination of nearly two decades of research and development as it prepares for first-in-human (FIH) clinical studies of its revolutionary accommodating intraocular lens (the “Ocumetics Lens”). “This moment is nothing short of transformational,”... Read more